Sign In
Buy BPTH
$0.0300
+0.0066 (+28.21%)
At Close: Jun 03, 2026
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
05:46pm, Wednesday, 05'th Jun 2024
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal deliver
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
04:55pm, Tuesday, 04'th Jun 2024
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024. To view the
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Positive Results from Interim Analy
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
07:00am, Friday, 24'th May 2024
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
05:00pm, Thursday, 23'rd May 2024
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
11:04am, Wednesday, 15'th May 2024
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and
Bio-Path Holdings Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 15'th May 2024
Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
07:00am, Wednesday, 08'th May 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12:14pm, Friday, 19'th Apr 2024
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
11:16am, Friday, 19'th Apr 2024
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
01:57pm, Thursday, 18'th Apr 2024
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi
Why Is Bio-Path (BPTH) Stock Up 89% Today?
10:28am, Thursday, 18'th Apr 2024
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002. This clinical trial is focusing on the use of BP
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell's Ability to Produce Cancer Enabling Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetocl
Bio-Path Holdings Expands Global Patent Portfolio
07:00am, Monday, 15'th Apr 2024
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform
Bio-Path Holdings shares sink 6% after deal for at-the-market offering
07:14pm, Thursday, 04'th Apr 2024
Shares of Bio-Path Holdings BPTH, -0.06% fell late Thursday after the company said it had reached a deal for an at-the-market share offering.
